AAD 2026: Acclaro to Highlight Expanding Clinical Uses of UltraClear 2910 nm Fiber Laser
Key Takeaways
- New data on Acclaro’s UltraClear®2910 nm fiber laser platform will be presented at the 2026 AAD Annual Meeting, highlighting expanding dermatologic applications.
- Planned sessions will explore use in resurfacing, scar revision, and treatment of anatomically challenging areas.
- Evidence to be shared includes real-world outcomes, though detailed study data have not yet been published.
Emerging clinical data on Acclaro’s UltraClear® 2910 nm fiber laser is set to be presented during multiple sessions at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado from March 26 through 31. The technology, a cold ablative fiber laser system, is expected to be featured in oral presentations and industry-supported educational sessions focused on evolving applications in laser dermatology.
According to meeting materials, investigators will examine the device’s use across a range of indications, including skin resurfacing, acne scarring, dyspigmentation, and treatment of anatomically sensitive areas such as periorbital and perioral skin. Additional sessions are expected to highlight its application in laser tissue coring techniques for scar revision and structural skin remodeling.
In addition to formal presentations, a series of “Fiber Focus Sessions” will be showcased at Acclaro’s exhibit booth (#3855), where faculty plan to review practical applications of the technology. These sessions are expected to highlight protocol customization using multi-mode settings, approaches for treating skin of color, and techniques for addressing difficult-to-treat areas. Real-world use cases, including patient-reported outcomes related to tolerability and recovery, are also anticipated to be discussed.
Planned presentations will further address treatment parameters intended to support precision and efficiency across indications. Reported outcomes to be discussed include patient satisfaction, procedural tolerability, and recovery time; however, specific quantitative data, study designs, and statistical analyses have not been detailed in the materials provided.
"As pioneers in advanced treatments, we increasingly look for technologies that deliver meaningful clinical outcomes while fitting into the realities of modern patient lifestyles," said cosmetic laser expert Paul M. Friedman, MD, Dermatology and Laser Surgery Center, Houston, TX. "UltraClear's next gen 2910nm fiber laser technology enables us to treat more patients and more indications across a diversity of skin types with a level of precision, safety and efficiency that has made it a workhorse in our practice for nearly four years."
Additional faculty expected to participate include Glynis Ablon, MD; E. Victor Ross, MD; Joel Cohen, MD; Eric Bernstein, MD; and Roy Geronemus, MD.